Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome

Rheumatology (United Kingdom)

Volumn 55, Issue 8, 2016, Pages 1403-1411

  Oku, Kenji ^a   Amengual, Olga ^a   Hisada, Ryo ^a   Ohmura, Kazumasa ^a   Nakagawa, Ikuma ^a   Watanabe, Toshiyuki ^a   Bohgaki, Toshiyuki ^a   Horita, Tetsuya ^a   Yasuda, Shinsuke ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti C1q antibodies; Anti phospholipid syndrome; Complement activation

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A [DEARGININE]; DNA ANTIBODY; HEPARIN; PHOSPHOLIPID ANTIBODY; SM ANTIBODY; WARFARIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARINIZATION; HUMAN; IMMUNOPATHOGENESIS; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORBIDITY; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; PREDICTIVE VALUE; PREGNANCY MORBIDITY; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; YOUNG ADULT; IMMUNOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; THROMBOSIS; YOUNG ADULT;

EID: 84988643327     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew196     Document Type: Article

References (41)

1. Ruffatti A, Del Ross T, Ciprian M et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009;68:397-9.
2. Ruiz-Irastorza G, Crowther M, Branch W. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
3. Atsumi T, Amengual O, Koike T. Antiphospholipid syndrome: pathogenesis. In: Lahita R, ed. Systemic lupus erythematosus. 5th edn. San Diego: Academic press, 2010: 945-66.
4. Cook HT, Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Prac Rheumatol 2006;2:330-7.
5. Oku K, Atsumi T, Bohgaki M. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-5.
6. Pierangeli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-50.
7. Meroni PL, Borghi MO, Raschi E et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011;7:330-9.
8. Avalos I, Tsokos GC. The role of complement in the antiphospholipid syndrome-associated pathology. Clin Rev Allergy Immunol 2009;36:141-4.
9. Holers VM, Girardi G, Mo L. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
10. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002;61 (Suppl 2):ii46-50.
11. Onuora S. Connective tissue diseases: a new therapeutic approach for APS? Nat Rev Rheumatol 2014;10:259.
12. Lu JH, Teh BK, Wang L. The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol 2008;5:9-21.
13. Böttcher A, Gaipl US, Fürnrohr BG et al. Involvement of phosphatidylserine, alphavbeta3, CD14, CD36, and complement C1q in the phagocytosis of primary necrotic lymphocytes by macrophages. Arthritis Rheum 2006;54:927-38.
14. Bradley AJ, Maurer-Spurej E, Brooks DE. Unusual electrostatic effects on binding of C1q to anionic liposomes: role of anionic phospholipid domains and their line tension. Biochemistry 1999;38:8112-23.
15. Trendelenburg M, Lopez-Trascasa M, Potlukova E et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006;21:3115-21.
16. Gunnarsson I, Rönnelid J, Huang YH et al. Association between ongoing anti-Clq antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997;36:32-7.
17. Hogarth MB, Norsworthy PJ, Allen PJ et al. Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin Exp Immunol 1996;104:241-6.
18. Antes U, Heinz HP, Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum 1988;31:457-64.
19. Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1qcontaining immune complexes. J Clin Invest 2004;114:679-88.
20. Horita T, Atsumi T, Yoshida N et al. STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann Rheum Dis 2009;68:1366-7.
21. Yin H, Borghi MO, Delgado-Vega AM et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009;60:2468-71.
22. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
23. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
24. Harris EN, Gharavi AE, Patel SP, Hughes GR, Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-22.
25. Amengual O, Atsumi T, Khamashta MA et al. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
26. Brandt JT, Triplett DA, Alving B, Scharrer I, Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
27. Swadzba J, Iwaniec T, Pulka M et al. Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost 2011;9:1776-83.
28. Otomo K, Atsumi T, Amengual O et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64:504-12.
29. Atsumi T, Amengual O, Yasuda S et al. Antiprothrombin antibodies-are they worth assaying? Thromb Res 2004;114:533-8.
30. Katsumata Y, Miyake K, Kawaguchi Y et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 2011;63:2436-44.
31. Kallenberg CG. Anti-C1q autoantibodies. Autoimmunity Rev 2008;7:612-5.
32. Samarkos M, Davies KA, Gordon C et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology 2001;40:1026-32.
33. Guerin J, Casey E, Feighery C, Jackson J. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity 1999;31:109-16.
34. Amengual O, Atsumi T, Khamashta MA et al. IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al. Arthritis Rheum 1998;41:1513-5.
35. Païdassi H, Tacnet-Delorme P, Garlatti V et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol 2008;180:2329-38.
36. Païdassi H, Tacnet-Delorme P, Verneret M et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol 2011;408:277-90.
37. Martin M, Leffler J, Blom AM. Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem 2012;287:33733-44.
38. Belmont HM, Hopkins P, Edelson HS et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986;29:1085-9.
39. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest 2012;42:1126-35.
40. Romay-Penabad Z, Liu XX, Montiel-Manzano G et al. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007;1108:554-66.
41. Vanhecke D, Roumenina LT, Wan H et al. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis Rheum 2012;64:3706-14.